KPTI

Karyopharm Therapeutics Inc

Sep 16 • 04:00PM ET

6.26

0.00 0.00 %

Healthcare • Biotechnology • USA • NASD

Peers: BMY MRK GILD JNJ VRTX AMGN REGN PFE BIIB LLY

Index	-	P/E	-	EPS (ttm)	-14.61	Insider Own	8.21%	Shs Outstand	8.65M	Perf Week	-1.11%
Market Cap	54.28M	Forward P/E	-	EPS next Y	-7.77	Insider Trans	-0.56%	Shs Float	7.96M	Perf Month	5.74%
Enterprise Value	193.20M	PEG	-	EPS next Q	-3.40	Inst Own	59.73%	Short Float	27.41%	Perf Quarter	37.89%
Income	-123.57M	P/S	0.40	EPS this Y	17.50%	Inst Trans	17.33%	Short Ratio	13.40	Perf Half Y	1.95%
Sales	137.27M	P/B	-	EPS next Y	32.51%	ROA	-77.51%	Short Interest	2.18M	Perf YTD	-38.29%
Book/sh	-27.63	P/C	1.05	EPS next 5Y	51.57%	ROE	-	52W High	16.95 -63.07%	Perf Year	-43.28%
Cash/sh	5.96	P/FCF	-	EPS past 3/5Y	27.56% 27.91%	ROIC	-	52W Low	3.51 78.35%	Perf 3Y	-92.20%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-11.54% 28.85%	Gross Margin	96.14%	Volatility	8.49% 11.54%	Perf 5Y	-97.27%
Dividend TTM	-	EV/Sales	1.41	EPS Y/Y TTM	-22.78%	Oper. Margin	-83.93%	ATR (14)	0.55	Perf 10Y	-97.14%
Dividend Ex-Date	-	Quick Ratio	0.94	Sales Y/Y TTM	-5.77%	Profit Margin	-90.02%	RSI (14)	52.25	Recom	2.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.99	EPS Q/Q	-45.40%	SMA20	-5.87%	Beta	0.34	Target Price	19.17
Payout	-	Debt/Eq	-	Sales Q/Q	-11.35%	SMA50	18.92%	Rel Volume	0.17	Prev Close	6.26
Employees	279	LT Debt/Eq	-	Earnings	Aug 11 BMO	SMA200	-7.81%	Avg Volume	162.78K	Price	6.26
IPO	Nov 06, 2013	Option/Short	Yes / Yes	EPS/Sales Surpr.	-5.84% -0.28%	Trades		Volume	27,108	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-16-25	Downgrade	H.C. Wainwright	Buy → Neutral
Jul-11-25	Resumed	H.C. Wainwright	Buy	$27
Jan-19-23	Initiated	Piper Sandler	Overweight	$8
Nov-04-22	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$7 → $10
Feb-09-22	Upgrade	JP Morgan	Underweight → Neutral	$8
Nov-19-21	Resumed	Morgan Stanley	Equal-Weight	$27 → $10
Aug-06-21	Downgrade	SVB Leerink	Outperform → Mkt Perform	$6
Aug-06-21	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$17 → $8
Aug-06-21	Downgrade	JP Morgan	Overweight → Neutral
Jul-02-20	Initiated	Morgan Stanley	Overweight	$34
Mar-04-20	Initiated	Barclays	Overweight	$30
Jan-17-20	Downgrade	Wedbush	Outperform → Neutral
Jul-23-19	Upgrade	JP Morgan	Neutral → Overweight	$8 → $16
Jul-05-19	Reiterated	Robert W. Baird	Outperform	$15 → $25
Jul-05-19	Reiterated	H.C. Wainwright	Buy	$29 → $32
Mar-01-19	Downgrade	JP Morgan	Overweight → Neutral	$21 → $7
Feb-28-19	Reiterated	BofA/Merrill	Underperform	$15 → $5
Feb-27-19	Downgrade	BofA/Merrill	Neutral → Underperform	$15 → $5
Jan-03-19	Upgrade	BofA/Merrill	Underperform → Neutral
Dec-03-18	Initiated	B. Riley FBR	Buy	$23

Show Previous Ratings

Sep-11-25 07:40AM	Karyopharm concludes enrolment in Phase III myelofibrosis treatment trial (Clinical Trials Arena) +6.92%
Sep-10-25 07:00AM	Karyopharm Announces Completion of Enrollment in the Phase 3 SENTRY Trial in Myelofibrosis (PR Newswire)
Sep-02-25 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Aug-12-25 03:03AM	Karyopharm Therapeutics Inc (KPTI) Q2 2025 Earnings Call Highlights: Navigating Financial ... (GuruFocus.com) +6.63%
Aug-11-25 07:00PM	Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
05:57PM	Loading…
05:57PM	Karyopharm Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	Karyopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company Progress (PR Newswire)
Aug-08-25 09:33AM	Karyopharm Therapeutics Inc (KPTI) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Aug-07-25 08:50AM	Collegium Pharmaceutical (COLL) Q2 Earnings and Revenues Surpass Estimates (Zacks)
Aug-05-25 07:00AM	Karyopharm to Report Second Quarter 2025 Financial Results on August 11, 2025 (PR Newswire)
Aug-01-25 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jul-30-25 07:35AM	United Therapeutics (UTHR) Misses Q2 Earnings Estimates (Zacks)
Jul-29-25 10:00AM	Karyopharm Therapeutics (KPTI) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks) -5.49%
Jul-01-25 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +5.73%
Jun-03-25 08:00AM	Karyopharm to Present at the Jefferies Global Healthcare Conference (PR Newswire)
04:05PM	Loading…
Jun-02-25 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
May-26-25 09:55AM	Here's Why Karyopharm Therapeutics (KPTI) Is a Great 'Buy the Bottom' Stock Now (Zacks)
May-19-25 09:55AM	Does Karyopharm Therapeutics (KPTI) Have the Potential to Rally 521.62% as Wall Street Analysts Expect? (Zacks)
07:00AM	Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference (PR Newswire)
May-14-25 09:31AM	Karyopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual Meeting (PR Newswire)
May-13-25 03:08AM	Karyopharm Therapeutics Inc (KPTI) Q1 2025 Earnings Call Highlights: Promising Clinical ... (GuruFocus.com) -20.00%
May-12-25 05:25PM	Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:26PM	Karyopharm Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Karyopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis that Further Suggests Selinexor May Lead to Meaningful Spleen Volume Reduction, Symptom Improvement, Hemoglobin Stabilization and Disease Modification (PR Newswire)
May-08-25 04:05PM	Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025 (PR Newswire)
May-05-25 05:10PM	Neurocrine Biosciences (NBIX) Q1 Earnings Miss Estimates (Zacks) -11.57%
May-01-25 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +8.88%
Apr-01-25 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -5.35% +14.69%
11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks)
Mar-03-25 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -8.81% -12.14%
08:40AM	Loading…
Feb-24-25 08:40AM	Karyopharm Announces 1-for-15 Reverse Stock Split (PR Newswire)
Feb-20-25 02:03AM	Karyopharm Therapeutics Inc (KPTI) Q4 2024 Earnings Call Highlights: Navigating Revenue ... (GuruFocus.com)
01:39AM	Q4 2024 Karyopharm Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-19-25 11:45AM	Karyopharm Therapeutics (KPTI) Q4 2024 Earnings Call Transcript (Motley Fool)
08:40AM	Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:45AM	Karyopharm Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
07:30AM	Karyopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company Progress (PR Newswire)
04:59AM	Karyopharm Therapeutics Inc (KPTI) Q4 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
Feb-12-25 07:00AM	Karyopharm to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025 (PR Newswire)
Feb-03-25 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jan-13-25 08:30AM	Karyopharm Announces Preliminary Unaudited 2024 Revenue and 2025 Objectives (PR Newswire) -6.37%
Jan-07-25 09:28AM	Why Karyopharm Therapeutics (KPTI) Is Among the Best Penny Stocks to Invest In According to Media? (Insider Monkey) -7.21%
Jan-02-25 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +20.01%
07:00AM	Karyopharm Announces the Appointment of Lori Macomber as Chief Financial Officer (PR Newswire)
Dec-09-24 08:00AM	Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications (PR Newswire)
Dec-03-24 07:00AM	Karyopharm Therapeutics Provides Endometrial Cancer Program Update (PR Newswire)
Dec-02-24 07:00AM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Nov-25-24 07:00AM	Karyopharm to Participate at the Piper Sandler 36th Annual Healthcare Conference (PR Newswire)
Nov-20-24 04:05PM	Karyopharm Therapeutics Announces the Appointment of Chief Accounting Officer (PR Newswire)
Nov-18-24 07:00AM	Karyopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and Exposition (PR Newswire)
Nov-06-24 02:08AM	Karyopharm Therapeutics Inc (KPTI) Q3 2024 Earnings Call Highlights: Navigating Growth Amidst ... (GuruFocus.com)
Nov-05-24 07:30PM	Antengene to Present Results from Two Late-Stage Studies of Selinexor Signaling Potential Clinical Breakthrough at ASH 2024 (PR Newswire) -9.36%
12:45PM	Karyopharm Therapeutics (KPTI) Q3 2024 Earnings Call Transcript (Motley Fool)
08:40AM	Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:37AM	Karyopharm Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress (PR Newswire)
Nov-04-24 07:14AM	Karyopharm Therapeutics Inc (KPTI) Q3 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Nov-01-24 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -8.75%
Oct-31-24 10:02AM	Karyopharm Therapeutics (KPTI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks) +17.81%
08:00AM	Karyopharm to Report Third Quarter 2024 Financial Results on November 5, 2024 (PR Newswire)
07:30AM	Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis (PR Newswire)
Oct-30-24 04:30PM	Karyopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024 (PR Newswire)
Oct-25-24 01:01PM	Highbridge Capital Management's Strategic Acquisition of Karyopharm Therapeutics Shares (GuruFocus.com)
Oct-17-24 10:35PM	Antengene Announces XPOVIO (selinexor) Approved for Its Third Indication in South Korea, Bringing Fresh Hope to Patients with MM in the Country (PR Newswire)
Oct-01-24 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -8.75% +16.70%
Sep-23-24 05:00AM	Antengene Announces XPOVIO (selinexor) Approved for Commercialization in Thailand (PR Newswire) -5.42%
Sep-05-24 09:35AM	Down -12.14% in 4 Weeks, Here's Why Karyopharm Therapeutics (KPTI) Looks Ripe for a Turnaround (Zacks) +11.93%
Sep-03-24 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -5.29%
07:00AM	Karyopharm to Participate at Upcoming Investor Conferences (PR Newswire)
Sep-02-24 05:52AM	Pipeline Moves: Investigator-led oncology cell therapy trial terminated (Clinical Trials Arena)
Aug-07-24 02:56AM	Q2 2024 Karyopharm Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-06-24 10:30PM	Karyopharm Therapeutics (KPTI) Q2 2024 Earnings Call Transcript (Motley Fool)
09:25AM	Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
08:21AM	Karyopharm Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	Karyopharm Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress (PR Newswire)
Aug-01-24 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -6.58%
Jul-31-24 04:05PM	Karyopharm to Report Second Quarter 2024 Financial Results on August 6, 2024 (PR Newswire) -6.72%
Jul-24-24 11:24PM	Karyopharm Therapeutics Inc. (KPTI): Is This One-Dollar Stock a Strong Buy Right Now? (Insider Monkey)
Jul-15-24 10:56AM	Karyopharm Therapeutics Inc. (KPTI): Is This Penny Stock A Good Buy Right Now? (Insider Monkey)
Jul-05-24 09:10AM	XPOVIO (selinexor) Approved for New Indication in DLBCL in China, Bringing a New Treatment Option to Patients in the Country (PR Newswire)
Jul-01-24 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -6.01%
Jun-26-24 04:42AM	Antengene Announces XPOVIO (selinexor) National Health Insurance Service Approval for Reimbursement in South Korea (PR Newswire) -8.71%
Jun-03-24 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -6.14%
Jun-01-24 01:45PM	Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates (PR Newswire)
May-29-24 04:05PM	Karyopharm to Participate at the Jefferies Global Healthcare Conference (PR Newswire)
May-23-24 06:45AM	The Next Novavax? 3 Biopharma Stocks to Buy Before They Boom (InvestorPlace)
May-09-24 11:10AM	Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:02AM	Karyopharm Therapeutics Inc (KPTI) Q1 2024 Earnings Call Transcript Highlights: Navigating ... (GuruFocus.com)
May-08-24 10:36PM	Q1 2024 Karyopharm Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -7.27%
04:45PM	Karyopharm Therapeutics (KPTI) Q1 2024 Earnings Call Transcript (Motley Fool)
04:05PM	Karyopharm to Participate at the 2024 RBC Capital Markets Global Healthcare Conference (PR Newswire)
12:54PM	KPTI Stock Earnings: Karyopharm Therapeutics Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
09:12AM	Karyopharm Therapeutics Reports Q1 2024 Financial Results: A Detailed Review (GuruFocus.com)
07:41AM	Karyopharm Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
07:30AM	Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress (PR Newswire)
07:30AM	Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029 (PR Newswire)
May-02-24 04:30PM	Karyopharm to Report First Quarter 2024 Financial Results on May 8, 2024 (PR Newswire)
May-01-24 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Apr-24-24 04:01PM	Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting (PR Newswire)
Apr-01-24 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -11.71%

Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A, Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008, and is headquartered in Newton, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Paulson Richard A.	President and CEO	Sep 15 '25	Sale	6.43	1,257	8,083	84,046	Sep 16 04:35 PM
Mano Michael	SVP, General Counsel&Secretary	Sep 15 '25	Sale	6.43	234	1,505	21,425	Sep 16 04:34 PM
Poulton Stuart	EVP, Chief Development Officer	Sep 15 '25	Sale	6.43	401	2,578	27,710	Sep 16 04:33 PM
Rangwala Reshma	EVP & Chief Medical Officer	Sep 15 '25	Sale	6.43	408	2,623	29,390	Sep 16 04:32 PM
Cheng Sohanya Roshan	EVP & Chief Commercial Officer	Sep 15 '25	Sale	6.43	325	2,090	35,856	Sep 16 04:31 PM
Abate Kristin	Chief Accounting Officer	Sep 15 '25	Sale	6.43	23	148	10,408	Sep 16 04:30 PM
Abate Kristin	Chief Accounting Officer	Sep 03 '25	Sale	6.78	12	81	9,463	Sep 04 04:53 PM
Poulton Stuart	EVP, Chief Development Officer	Jul 29 '25	Sale	4.37	191	835	27,223	Jul 30 04:56 PM
Abate Kristin	Chief Accounting Officer	Jul 22 '25	Sale	4.00	238	952	9,475	Jul 23 05:18 PM
Paulson Richard A.	President and CEO	May 06 '25	Sale	7.12	236	1,680	82,503	May 07 05:03 PM
Rangwala Reshma	EVP & Chief Medical Officer	Apr 23 '25	Sale	6.17	419	2,585	28,853	Apr 24 04:40 PM
Paulson Richard A.	President and CEO	Apr 04 '25	Sale	3.74	245	916	82,739	Apr 07 04:59 PM
Cheng Sohanya Roshan	EVP & Chief Commercial Officer	Mar 04 '25	Sale	6.29	3,445	21,669	34,314	Mar 06 04:27 PM
Paulson Richard A.	President and CEO	Mar 04 '25	Sale	6.29	11,694	73,555	82,984	Mar 06 04:27 PM
Rangwala Reshma	EVP & Chief Medical Officer	Mar 04 '25	Sale	6.29	3,587	22,562	29,272	Mar 06 04:26 PM
Poulton Stuart	EVP, Chief Development Officer	Mar 04 '25	Sale	6.29	3,548	22,317	27,414	Mar 06 04:24 PM
Mano Michael	SVP, General Counsel&Secretary	Mar 04 '25	Sale	6.29	2,793	17,568	21,047	Mar 06 04:13 PM
Poulton Stuart	EVP, Chief Development Officer	Feb 18 '25	Sale	0.63	5,914	3,726	320,714	Feb 19 04:17 PM
Paulson Richard A.	President and CEO	Feb 04 '25	Sale	0.65	4,099	2,664	1,120,158	Feb 05 04:16 PM
Paulson Richard A.	President and CEO	Jan 06 '25	Sale	0.78	4,055	3,175	1,124,257	Jan 07 04:03 PM
Paulson Richard A.	President and CEO	Dec 04 '24	Sale	0.81	3,620	2,932	1,128,312	Dec 05 04:15 PM
Paulson Richard A.	President and CEO	Nov 05 '24	Sale	0.91	3,675	3,346	1,131,932	Nov 06 04:06 PM
Paulson Richard A.	President and CEO	Oct 04 '24	Sale	0.88	3,607	3,172	1,135,607	Oct 07 04:44 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KPTI

Karyopharm Therapeutics Inc

Upgrade your FINVIZ experience